Abstract: Chemotherapy is still the role treatment in advanced gastric cancer by now, but no standard approach has been adopted. Chemotherapy can prolong median overall survival and improve quality of life compared with the best supportive care alone. Recent years, with the emergence of various new agents, chemotherapy regimens continuous improvement. As a result, the response rate and overall survival of advanced gastric cancer being further improved. Meanwhile, with a greater understanding of the molecular biolo- gy of gastric cancer, molecular biological targeted therapies that target HER-2, EGFR and VEGF become the focus of the comprehensive treatment. Chemotherapy combined targeted therapy have shown great benefit and perspective in treatment of advanced gastric cancer, but their usage should be fiarther modified and optimized in clinical trials and practices.